Johnson & Johnson has agreed to pay $5.5 billion to resolve roughly 76,000 US lawsuits alleging its talc-based baby powder caused ovarian cancer, ending litigation that has run for more than a decade. The healthcare giant will pay up to $3bn in 2027, with the balance following from 2028, and the deal must be accepted by 95% of claimants before it becomes final, according to reporting from the Financial Times and the Guardian.
The number matters less to the insurance market than how J&J got here. The company spent years trying to route the claims through a bankruptcy manoeuvre known as the "Texas two-step," splitting off a subsidiary to absorb the liability. Courts rejected the plan three times. J&J then returned to the tort system in spring 2025, saying it would litigate rather than settle, and won a string of trials on that basis. That confidence held until a New Jersey federal judge ruled this month that plaintiffs would need specific causation evidence many didn't have, a ruling that appears to have pushed both sides back toward a deal.
Talc has been one of the reference points in the broader conversation around social inflation and mass tort exposure reshaping US casualty pricing. Insurance Business has covered how nuclear verdicts and third-party litigation funding are pushing UK brokers and insurers with US casualty exposure to reassess appetite, even where they sit several steps removed from the original defendant. The $5.5bn figure, down from the $8.9bn J&J had proposed in 2023, gives carriers and reinsurers a fresher data point for reserving against similar long-tail product liability exposures. It's worth noting the deal only closes off existing claims, not future ones.
J&J's own insurance position adds another layer to this. The company stopped buying new product liability coverage in 2005 and now relies heavily on self-insurance, including through its own captive, Middlesex Assurance. A separate New Jersey coverage action, Atlanta International Insurance Co, et al v Johnson & Johnson, et al, has for years pitted J&J against a group of legacy carriers on cover written before 2005, including Travelers, Chubb, Allstate, Everest Re, TIG, North River and Wausau, over how much of the talc liability those older policies actually have to pick up. That fight over legacy limits, running in parallel to the tort claims themselves, is likely to keep going even with Monday's settlement in place.
The exposure that hasn't gone away sits closer to home. Kenvue, J&J's former consumer health arm, took on responsibility for talc claims outside North America when it was spun off in 2023, and now finds itself facing a High Court claim covering more than 7,000 people and reportedly valued above £1bn. One report has called it "the largest product liability case in UK history." Filed in October 2025, the claim alleges J&J knew its talc products contained carcinogenic fibres for decades but kept selling them in Britain until recent years. It's entirely unaffected by Monday's US settlement.
Casualty reinsurers are already flagging capacity concerns tied to social inflation and litigation funding. If the UK case goes to trial rather than settling early, it will show how far those US dynamics have travelled into the London liability market.
